Flurazepam

Summary

Flurazepam (CHEMBL968) is an approved small-molecule anticonvulsant (ATC N05CD01); indicated across 5 conditions including anxiety and dementia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CD01
• Indications: 5 conditions
• Clinical trials: 2
• Chemistry: 387.9 Da · C21H23ClFN3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL968
Name	Flurazepam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3393
ChEBI	CHEBI:5128
ATC	N05CD01
Molecular formula	C21H23ClFN3O
Molecular weight	387.9
InChIKey	SAADBVWGJQAEFS-UHFFFAOYSA-N

SMILES: CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F

IUPAC name: 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one

ChEBI definition: A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.

Pharmacological roles (ChEBI): sedative, anticonvulsant, GABAA receptor agonist, anxiolytic drug.

Also known as: Flurazepam, Insumin, SID26757995, flurazepam, SID144205754, FLURAZEPAM, SID170465018

Parent form; salt/anhydrous children: CHEMBL3989724

Patent coverage: 4,433 distinct patent families (17,469 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 17,458 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: 5-hydroxytryptamine receptor 3A, 5-hydroxytryptamine receptor 1A, D(3) dopamine receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Gamma-aminobutyric acid receptor subunit alpha-1, Growth hormone secretagogue receptor type 1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	7.29	AC50	51.2	nM	CHEMBL_ACT_25131254
OPRK1	6.68	AC50	209.6	nM	CHEMBL_ACT_25130048
KCNH2	6.05	AC50	896	nM	CHEMBL_ACT_25118842
HTR1A	5.26	AC50	5473	nM	CHEMBL_ACT_25164710
DRD3	5.08	AC50	8400	nM	CHEMBL_ACT_25194197

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050
insomnia	1	MONDO:0013600	EFO:0004698

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT02350309	PHASE1	COMPLETED	Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).